Selected Updates in Cardiovascular Pharmacotherapy: Non-Statin Therapy and A.Fib Stroke Prevention

Activity Details
  • Credit Amounts:
    • CME: 1.00
    • CPE: 1.00
  • Cost: Free
  • Release: Aug 22, 2018
  • Expires: Aug 22, 2021
  • Estimated Time to Complete:
    1 Hour(s)
  • System Requirements:
  • Average User Rating:
    ( Ratings)

Faculty

Mary Covell Mary Covell, PharmD, MPH
Pharmacy Clinical Coordinator
Ephraim McDowell Regional Medical Center
Danville, Kentucky

Brett A.  Vickey Brett A. Vickey, PharmD, BCPS
Clinical Pharmacist
Ephraim McDowell Regional Medical Center
Danville, Kentucky

Needs Statement

This will be two part focused update on cardiovascular pharmacotherapy relevant to patients in our health system - both inpatient and ambulatory care setting.

The Atrial Fibrillation section will emphasize appropriate oral anticoagulation selection prior to discharge while highlighting DOAC therapies as an opportunity to pro actively facilitate transitions and promote comprehensive patient counseling. A subsidiary focus will be placed on rate vs rhythm pharmacoptherapy selection with associated laboratory and parapsychological considerations.

Non-statin therapy section will focus on identifying patients that are candidates for therapy, discussing the various agents available currently on the market, and agents expected to be released in the near future. Focus will be placed on the economic considerations and prescribing patterns.

Target Audience

Physicians, Nurse Practitioners, Pharmacists, Residents and Technicians

Objectives

Upon completion of this educational activity, you will be able to:

Part 1:

  1. Discuss DOAC therapies available and appropriate patient candidates
  2. Describe pharmacotherapy options and pertinent considerations in AF
  3. Review Pathophysiological and demographic review

Part 2:

  1. Define populations that may require non-statin therapy for secondary prevention
  2. Review the available non-statin therapies from efficacy and public health perspective
  3. Describe how to formulate a utilization algorithm of non-statin therapy for secondary prevention
  4. Discuss emerging non-statin therapies in development

Accreditation

CME
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of the University of Kentucky College of Medicine, and Ephraim McDowell Regional Medical Center. The University of Kentucky College of Medicine is accredited by the ACCME to provide continuing medical education for physicians.

The University of Kentucky College of Medicine designates this enduring material for a maximum of 1.00 AMA PRA Category 1 Credit(s)™. Physicians should only claim credit commensurate with the extent of their participation in the activity.

The University of Kentucky College of Medicine presents this activity for educational purposes only. Participants are expected to utilize their own expertise and judgment while engaged in the practice of medicine. The content of the presentations is provided solely by presenters who have been selected for presentations because of recognized expertise in their field.

ACGME Competencies

  • Patient care
  • Medical knowledge
  • Practice-based learning and improvement
  • Systems-based practice

CPE
ACPEThe University of Kentucky College of Pharmacy is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education.

This knowledge-based activity has been assigned UAN 0022-9999-18-147-H01-P and will award 1.00 contact hour (0.100 CEUs) of continuing pharmacy education credit in states that recognize ACPE providers.

Statements of participation will indicate hours and CEUs based on participation and will be issued online at the conclusion of the activity. Successful completion includes completing the activity, its accompanying evaluation and/or posttest (score 70% or higher) and requesting credit online at the conclusion of the activity. Credit will be uploaded to CPE Monitor, and participants may print a statement of credit or transcript from their NABP e-profile. The College complies with the Accreditation Standards for Continuing Pharmacy Education.

Faculty Disclosure

No speakers have any relevant financial relationships to disclose.

The material presented in this course represents information obtained from the scientific literature as well as the clinical experiences of the speakers. In some cases, the presentations might include discussion of investigational agents and/or off-label indications for various agents used in clinical practice. Speakers will inform the audience when they are discussing investigational and/or off-label uses.

Disclosure of a relationship is not intended to suggest or condone commercial bias in any presentation, but it is made to provide participants with information that might be of potential importance to their evaluation of a presentation.

Acknowledgement

This activity is jointly provided by the University of Kentucky and Ephraim McDowell Regional Medical Center.

CE Content Concerns

Policy

Concerns or complaints related to ACPE or ACCME standards may be submitted in writing to the Director of UK HealthCare CECentral by fax to 859-323-2920, or by mail to 2365 Harrodsburg Road, Ste B475, Lexington, KY 40504

Procedures

  • The Director or his/her designee will review, investigate, forward and/or respond to complaints and will put forth a best effort to adjudicate the issue(s), along with CECentral staff members, within two (2) weeks of receipt of the grievance or complaint.
  • If needed, concerns, complaints, or grievances will be brought before the UK HealthCare CECentral Advisory Board.
  • Issues regarding activity content also will be reviewed and addressed by the Activity Director.
  • A written decision will be issued in a timely manner by the Director of UK HealthCare CECentral or his/herdesignee.
  • Grievances will be considered when planning future activities.

Appeal Procedure

  • Persons who wish to appeal a decision should address the appeal by email, fax or in writing to the Director of UK HealthCare CECentral within two (2) weeks of receipt of the response.
  • The Director will bring the appeal to the UK HealthCare CECentral Advisory Board.
  • The results of the appeal will be sent to the participant no later than two (2) weeks following the meeting of the board.